Subcutaneous Immune Globulin for CIDP

Hizentra and HyQvia are subcutaneous immune globulins (SCIG) FDA-approved as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). MedRx Infusion dispenses both, delivers them with the supplies at no charge, and can send a skilled nurse from an accredited nursing agency to train the patient or caregiver to infuse at home.

SCIG as maintenance therapy for CIDP

SCIG is immune globulin infused under the skin with a small pump, rather than into a vein. In CIDP it is a maintenance therapy: both approved products are started in patients who have been treated with intravenous immune globulin (IVIG), to prevent relapse. The prescriber determines whether the subcutaneous route is appropriate.

For CIDP treatment as a whole, see CIDP treatment at home. For SCIG in other conditions, its supplies and its side effects, see SCIG at home.

The two products approved for CIDP

Each product's page gives its label, storage and the manufacturer's support program. The prescriber sets the dose and the schedule within the label.

Moving from IVIG to SCIG

The prescriber decides on the change and writes the new order. Hizentra's label starts it 1 week after the last IVIG infusion; HyQvia's label requires stable doses of IVIG first. Both labels are for maintenance: neither product is approved to start CIDP treatment.

For a patient already on IVIG, MedRx's intake team works with the prescriber's office on the change: it verifies benefits, obtains prior authorization where the plan requires it, and arranges delivery and the nurse's visit.

SCIG at home with MedRx

MedRx delivers the medication and supplies to the patient's door at no charge; depending on the therapy, supplies include needles, tubing and an infusion pump. Next-day delivery is available; timing varies by location.

A skilled, trusted and licensed nurse from an accredited nursing agency visits the home, can administer the infusion, and trains the patient or caregiver to give it. After training, the patient or caregiver infuses on the schedule the prescriber sets.

A MedRx pharmacist is available 24 hours a day, 7 days a week. MedRx's pharmacy team includes Ig Certified Pharmacists (IgCP), who hold a specialty certification in immune globulin therapy.

Medicare and insurance

Medicare Part B's durable medical equipment benefit covers subcutaneous immune globulin given at home through an external infusion pump. Under the Medicare contractors' coverage policy:

the product is an FDA-approved pooled plasma derivative labeled for subcutaneous administration
it is administered in the patient's home
the treating practitioner has determined that administration at home is medically necessary and appropriate
the patient has a primary immune deficiency disorder, or a diagnosis of CIDP that has responded to IVIG treatment

For CIDP, the policy's billing article lists Hizentra and HyQvia. Intravenous immune globulin is not covered under that policy, and Medicare's separate benefit for IVIG at home applies to primary immune deficiency disease only.

Medicare Advantage plans have their own prior authorization requirements, each state runs its own Medicaid program, and commercial plans commonly require prior authorization for immune globulin. MedRx's intake team verifies the patient's coverage before the first delivery. See insurance and prior authorization.

Where out-of-pocket costs are a barrier, MedRx helps patients find and apply for copay assistance, grants and other financial aid. CSL Behring and Takeda also run patient support programs, named on each medication page.

Key facts

Organization: MedRx Infusion Clinical Pharmacy
What we do: A home infusion pharmacy and specialty pharmacy, with infusion nurses who visit patients at home and a pharmacist on call 24 hours a day, 7 days a week.
Where: Pharmacy at 417 N Oak St, Inglewood, CA 90302. Licensed in 44 states, the District of Columbia and Puerto Rico. See every place we serve
Accreditation: URAC (Specialty Pharmacy) and ACHC (Accreditation Commission for Health Care).
Phone, 24 hours: (844) 671-2600
Fax: (844) 671-2601

Accurate as of October 19, 2026

Questions about SCIG for CIDP

01Is subcutaneous immune globulin FDA-approved for CIDP?

Yes. Hizentra and HyQvia are approved for adults with CIDP as maintenance therapy to prevent relapse of neuromuscular disability and impairment. Both are started after treatment with IVIG.

02Does Medicare cover Hizentra or HyQvia at home for CIDP?

Medicare's durable medical equipment policy covers subcutaneous immune globulin at home for a patient whose CIDP has responded to IVIG, when the treating practitioner determines that administration at home is medically necessary and appropriate. Its billing article lists Hizentra and HyQvia for CIDP. MedRx's intake team checks the patient's coverage before the first delivery.

03How often is SCIG infused for CIDP?

The prescriber sets the schedule within the label. Hizentra's label gives weekly infusion for CIDP, in 1 or 2 sessions over 1 or 2 consecutive days. HyQvia starts at the same frequency as the patient's previous IVIG treatment.

04Who gives the infusion at home?

After training by a nurse, the patient or a caregiver. A skilled nurse from an accredited nursing agency can also administer it.

05Is Vyvgart Hytrulo a subcutaneous immune globulin?

No. Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a neonatal Fc receptor (FcRn) blocker given as a subcutaneous injection, FDA-approved for adults with CIDP. See CIDP treatment at home.